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Abstract
Background: Chronic kidney disease (CKD) is a global public health threat, associated with an
alarming increase in morbidity and mortality. The importance is the worldwide increase in its
incidence and prevalence.
Methods: In this cross-sectional study, we estimate the prevalence and determine the associated
factors of chronic kidney disease in a representative sample of 10063 participants aged over 20
years, in Tehran, Iran. Chronic kidney disease was defined as estimated glomerular filtration rate
less than 60 mL/min/1.73 m2. Glomerular filtration rate was estimated from abbreviated prediction
equation provided by the Modification of Diet in Renal Disease study (MDRD).
Results: Overall prevalence of CKD with the abbreviated MDRD equation was 18.9% (95%
confidence interval (CI) 18.2, 20.6). Age adjusted prevalence of CKD was 14.9% (95%CI 14.2, 15.6).
Factors associated to CKD include age(years)(odds ratio(OR) 1.1, 95% CI 1.0 to 1.2), female
gender (OR 3.1, 95% CI 2.6, 3.7), BMI (BMI 25 to <30 OR 1.5, 95% CI 1.3, 1.8 and BMI ≥ 30 OR 1.6,
95% CI 1.3, 2.0), high waist circumference (OR 1.2, 95% CI 1.1, 1.4), hypertension (OR 1.2, 95% CI
1.1, 1.4), and dyslipidemia (OR 1.3, 95% CI 1.1, 1.5).
Conclusion: CKD with its high prevalence poses a definite health threat in Iran.
Background
Chronic kidney disease (CKD) is a worldwide public
health problem, associated with a considerable increase in
morbidity and mortality. Of importance is its global
increase in incidence and prevalence [1, 2]. Outcomes of
CKD include not only progression to kidney failure but
also complications of reduced kidney function and
increased risk of cardiovascular disease and all-cause
mortality overall, although patients with CKD are far
more likely to die, principally from cardiovascular disease,
than to develop kidney failure [3-5]. However CKD is often
undiagnosed and its complications are often untreated
[6-8]. There is convincing evidence that CKD can be
prevented or its progression delayed, if effective manage-
ment is initiated in time. Hence, identifying patients with
CKD and providing prompt intervention play an impor-
tant role in appropriate management of CKD [9-11].
The prevalence of CKD has been addressed in several
studies. In the United States, cross-sectional analysis of
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ination Surveys (NHANES) showed that the prevalence
of CKD increased from 10.0% in 1988–1994 to 13.1% in
1999–2004 [2]. Studies from Europe, Australia, and Asia,
also, confirm the high prevalence of CKD. The pre-
valence of reduced GFR in Australia was 11.2 percent
[12]. Singapore, a south-east Asian country, reported a
CKD prevalence of 10.1 percent, while the prevalence of
CKD in Japanese general population was reported to
be 18.7% [13, 14]. However, much less information is
available on prevalence rates elsewhere, from the
developing regions of the Middle East in particular.
There is strong evidence that development and progres-
sion of CKD are outcomes of exposure to cardiovascular
disease risk factors [15]. In many studies, the known risk
factors for development and progression of CKD cited
are age, diabetes mellitus (DM), hypertension, obesity,
dyslipidemia and smoking [16-24].
To prevent and initiate appropriate management of
CKD, it is crucial to have precise prevalence rates. The
aim of this study was to estimate the prevalence and
determine the associated factors of CKD in a large
population based study in Tehran, Iran.
Methods
The Tehran Lipid and Glucose Study (TLGS) is an
ongoing population-based cohort study, with contin-
uous recruitment since December 1997, which has been
designed to determine risk factors for atherosclerosis in
Tehran's urban population and to develop population
based measures aimed at changing life styles and halting
the increasing trend of DM and dyslipidemia [25]. The
study is divided into two phases: a cross-sectional study
of the prevalence of non-communicable diseases such as
DM and cardiovascular disease and their associated risk
factors, and a prospective 20-year follow up study. A
multistage stratified cluster random sampling technique
was used to select 15005 people aged ≥ 3 years from the
urban district 13 of Tehran, the capital of the Islamic
Republic of Iran. During sampling, the list of all
households under coverage of the district's three
healthcare centers (the official bodies responsible for
vaccination programs and collection of health-related
statistics in a district) was used; a random sample of the
households, stratified by healthcare centre to achieve a
distribution similar to the original population, was
chosen; from each household, all members above the
age of 3 years were recruited. The study began in
December 1997 and the cross-sectional phase completed
in 2000. District 13 is located in the centre of Tehran and
the age distribution of its population is representative of
the overall population of Tehran. Designated residents
were sent an invitation requesting their participation
[25]. The crude response rate in the TLGS participants
was approximately 57.5%. The reason for no response
have been investigated and there was no significant
difference regarding age and sex between responders and
nonresponders [26].
At the beginning of the cross-sectional phase, all
participants provided written informed consent, which
was approved by the institutional ethics committees
(Research Institute for Endocrine Sciences) and was
conducted in accordance with the principles of the
Declaration of Helsinki. Thereafter, demographic data
collection and anthropometric examinations were
undertaken by trained general physicians. Weight was
recorded using a Seca 707 weighing machine (range 0.1–
150 kg) with an accuracy of up to 100 g. The precision of
the machine was checked after every 10 measurements.
Height was measured without shoes using a tape
stadiometer with a minimum measurement of 1 mm.
Body mass index (BMI) was calculated by dividing
weight (in kg) by height squared (in m
2). Systolic and
diastolic blood pressures were measured using a stan-
dardized mercury sphygmomanometer on the right arm
after a 15-min rest in the supine position. Blood samples
were drawn between 08.00 and 09.00 h into vacutainer
tubes after a 12–14-h overnight fast according to the
standardized protocol of the TLGS. Then subjects
underwent a standardized 75-g oral glucose tolerance
test (OGTT). All samples were centrifuged within 35–40
min of collection (2500 r.p.m. (1000 g), 30 min and 4°
C). All blood biochemical analyses were performed at
the TLGS research laboratory on the day of blood
collection. Analyses were performed using the Selectra
2
® autoanalyser (Vital Scientific, Spankeren, the Nether-
lands). Plasma glucose was assayed using the glucose
oxidase method [Pars Azmon Inc., Iran; with inter- and
intra-assay coefficients of variation (CVs) of 3% and
0.8%, respectively]. For 2 h-OGTT, 75 g glucose was
administrated orally and plasma glucose was measured
2 hours later (2 h-PG) [27].
Plasma total cholesterol(TC) and triglyceride(TG) levels
were measured using enzymatic colorimetric kits (Pars
Azmon Inc.; inter- and intraassay CVs were 2 and 0.5%
for TC and 1.6 and 0.6% for TGs, respectively). Sera
creatinine levels were measured according to the
standard colorimetric Jaffe_Kinetic reaction method
(Pars Azmon Inc., Iran; with inter- and intra-assay CVs
of 2.5% and 1.9%, respectively, and sensitivity of 0.2
mg/dl). The assay range was 18–1330 μmol (0.2–15 mg/
dl). Reference intervals according to producer recom-
mendation were: 53–97 μmol (0.6–1.1 mg/dl) and 80–
115 μmol (0.9–1.3 mg/dl) in women and men
respectively in serum/plasma. Assay performance was
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Precinorm (cat. no. 1446070; Boehringer Mannheim,
Germany) for normal range and Precipath (cat. no.
171778; Boehringer Mannheim) for pathological ranges
[25].
From 15005 participants of the cross-sectional phase of
TLGS, we excluded subjects <20 years of age. Data of
10368 eligible individuals were gathered and 305
individuals, who had missing data for calculation of
creatinine, were excluded. Analysis was conducted on the
data of the remaining 10063 participants.
Definitions
According to the Kidney Disease Outcome Quality
Initiative (K/DOQI) guideline, chronic kidney disease
is defined as either kidney damage or Glomerular
Filtration Rate (GFR) <60 mL/min/1.73 m
2 (1.0 mL/s/
1.73 m
2) for >3 months. Kidney damage is defined as
pathologic abnormalities or markers of damage, includ-
ing abnormalities in blood or urine tests or imaging
studies [28]. For this study GFR was estimated from
abbreviated prediction equation provided by the Mod-
ification of Diet in Renal Disease (MDRD) study as
following:
Abbreviated MDRD study equation:
GFR = 186 × (SCr)
-1.154 × (Age)-
0.203 × (0.742 if female)
× (1.210 if African-American)
In this equation, GFR is expressed as mL/min per 1.73
m
2, and serum creatinine (Scr) is expressed as mg/dL
[29].
The classification of CKD by stages was done also
according to the Kidney Disease Outcome Quality
Initiative (K/DOQI) criteria as below:
Stage 1
Normal GFR (greater than 90 ml/min per 1.73 m
2 (1.50
mL/s/1.73 m
2)) and persistent albuminuria.
Stage 2
AG F Rb e t w e e n6 0t o8 9m l / m i np e r1 . 7 3m
2 (1.00 to
1.49 mL/s/1.73 m
2) and persistent albuminuria.
Stage 3
A GFR between 30 and 59 ml/min per 1.73 m
2 (0.50 to
0.99 mL/s/1.73 m
2).
Stage 4
A GFR between 30 and 15 ml/min per 1.73 m
2 (0.25 to
0.49 mL/s/1.73 m
2).
Stage 5
AGFRlessthan15ml/minper1.73m
2(0.25mL/s/1.73m
2)
or end-stage renal disease [28].
BMI (Body mass index) was categorized as 3 groups of <25
kg/m
2, 25 to <30 kg/m
2 (overweight), and ≥ 30 kg/m
2
(obese). Abnormal waist circumference was set as ≥ 102 cm
in men, and ≥ 88 cm in women according to the Third
Report of the National Cholesterol Education Program
(NCEP) Expert Panel on Detection, Evaluation, and
Treatment of High Blood Cholesterol in Adults (Adult
Treatment Panel III) [30]. Hypertension was defined
according to the Seventh Report of the Joint National
Committee (JNC7) on Prevention, Detection, Evaluation,
and Treatment of High Blood Pressure criteria as systolic
blood pressure ≥ 140 mmHg or diastolic blood pressures
≥ 90 mmHg, or patients taking antihypertensive agents
[31]. Dyslipidemia was defined according to the Executive
Summary of the Third Report of the National Cholesterol
Education Program (NCEP) Expert Panel on Detection,
Evaluation, and Treatment of High Blood Cholesterol in
Adults (Adult Treatment Panel III) as serum triglyceride of
≥ 200 mg/dl or cholesterol of ≥ 240 mg/dl and also
included subjects taking lipid lowering medications [30].
Smoking was defined as participants who smoked cigar-
ettes daily or occasionally or participants who smoked
before. DM (diabetes mellitus) defined according to the
criteria of the American Diabetes Association (ADA) as
fasting plasma glucose ≥ 126 mg/dl or 2-h postload ≥ 200
mg/dl, included patients who were known cases of diabetes
and use insulin or oral glucose-lowering agents [27].
Statistical Methods
All continuous data with normal distribution are expressed
as mean ± SD and skewed parameters as median,
interquartile 25–75% (IQ25–75), and categorical variables
are expressed as percentage. Age adjusted prevalence was
estimated with the reference population group of Iran
according to the data from the 1996 census. Difference for
continuous variables was assessed by using the t-test,
whereas difference for categorical variables was assessed
with the Chi Square Test. A multivariate logistic regression
model was used to estimate the odds ratio (OR) of related
factors with CKD. Age (years), sex (reference: male), BMI
(reference: < 25 kg/m
2), abnormal waist circumference,
hypertension, dyslipidemia, DM and smoking in dichot-
omous fashions were considered as independent variables.
All statistical analyses were performed by SPSS software
(version 15.0). Differences with probability values < 0.05
were considered statistically significant.
Results
The baseline characteristics of the study population are
listed in Table 1. A total of 10063 participants aged ≥ 20
BMC Public Health 2009, 9:44 http://www.biomedcentral.com/1471-2458/9/44
Page 3 of 8
(page number not for citation purposes)years were analyzed; while population age ranged
between 20 and 90 years, the participants were mostly
young and the mean age was 42.7 ± 14.9 years (median
and IQ25–75 41 and 31–54 years, respectively). Of the
total study population, 41.9% (n = 4223) were male. The
mean (± SD) of height for men and women were 169.7
(± 6.8) and 156.5 (± 6.1) respectively and the mean
(± SD) of weight for men and women were 74.3 (± 12.7)
and 67.3 (± 12.4) respectively. Normal BMI was detected
in 36.7% (n = 3614) of participants, the other 63.3%
(n = 6232) were overweight or obese; from the aspect of
abdominal obesity, 33.3% (n = 3349) had abnormal
waist circumference, which was more common in
women (48.9%, n = 2855) than in men (11.7%, n =
494). The prevalence of DM, hypertension and dyslipi-
demia was 13.7%, 25.8% and 44.3%, respectively. In our
population, 13.1% were smokers. The mean (± SD)
creatinine and eGFR were 1.1 (± 0.2) mg/dl (97.2 μmol/
L), and 70.6 (± 12.3) mL/min/1.73 m
2 (1.17 mL/s/1.73
m
2), respectively with minimum and maximum of 0.5
mg/dl (44.2 μmol/L) and 9.2 mg/dl (813.2 μmol/L) for
creatinine and, 5.9 mL/min/1.73 m
2 (0.09 mL/s/1.73
m
2) and 126 mL/min/1.73 m
2 (2.10 mL/s/1.73 m
2)f o r
eGFR, while the mean (± SD) of serum creatinine and
e G F Rf o rm e nw e r e1 . 2( ±0 . 2 )m g / d la n d7 2 . 9( ±1 2 . 2 )
mL/min/1.73 m
2 respectively and those of serum
creatinine and eGFR for women were 1.0 (± 0.1) mg/dl
and 69.0 (± 12.2) mL/min/1.73 m
2 (Figure 1).
Overall prevalence of CKD, based on eGFR calculated
with the abbreviated MDRD equation was 18.9% (95%
CI 18.2, 20.6); while age adjusted prevalence of CKD was
14.9% (95%CI 14.2, 15.6). From participants who had
CKD, 99.2% were in the stage 3 of CKD, 0.7% (n = 13)
i nt h es t a g e4a n do n l y0 . 1 %( n=2 )i nt h es t a g e5o f
CKD (Table 2). The prevalence of CKD increased with
increasing age, therefore the prevalence of CKD was
highest among people within the age group of ≥ 70
years. In each age group the prevalence of CKD in
women was higher than men (Figure 2).
In bivariate analysis, the factors significantly associated
with CKD other than older age were being female
gender, obesity, having diabetes mellitus (DM), being
hypertensive and having dyslipidemia, but nonsmoking
was associated with CKD (Table 3). Using multiple
logistic regression analysis, the multivariate-adjusted
ORs for presence of CKD were significant for age (OR
1.1, 95% CI 1.0, 1.2), female gender (OR 3.1, 95% CI
Table 1: Baseline characteristics of 10 063 participants of the
Tehran Lipid and Glucose Study (TLGS) aged 20 years and over.
n%
Gender (male) 4223 41.9
Age(years)
20–39 4782 47.6
40–59 3510 34.8
60–69 1325 13.2
≥ 70 446 4.4
Body mass index (kg/m
2)
≤ 25 3614 36.7
25–30 3951 40.1
≥ 30 2281 23.2
Abnormal waist circumference in men 494 11.7
Abnormal waist circumference in women 2855 48.9
Diabetes mellitus 1381 13.7
Hypertension 2593 25.8
Dyslipidemia 4462 44.3
Smoking 1300 13.1
Male Female
30 60 90 120
eGFR ml/min/1.73 m2
100
200
300
400
N
u
m
b
e
r
30 60 90 120
eGFR ml/min/1.73 m2
Figure 1
GFR distribution. Histograms demonstrating GFR
distribution for male and female participants of the Tehran
Lipid and Glucose Study (TLGS) aged 20 years and over.
Table 2: Prevalence of CKD among different age groups in 10 063
participants of the Tehran Lipid and Glucose Study (TLGS) aged
20 years and over.
Age groups n CKD% 95% CI
Men
20–39 1897 1.8 1.2–2.4
40–59 1413 12.0 11.1–12.9
60–69 651 33.5 29.9–37.1
≥ 70 262 50.0 44.0–56.0
Total 4223 13.1 12.1–14.1
Women
20–39 2885 4.6 3.8–5.4
40–59 2097 31.5 29.5–33.5
60–69 674 60.8 57.1–64.5
≥ 70 184 76.6 70.5–82.7
Total 5840 23.0 21.9–24.1
All
20–39 4782 3.5 3.0–4.0
40–59 3510 23.6 22.2–25.0
60–69 1325 47.4 44.7–56.5
≥ 70 446 61.0 56.5–65.5
Total 10063 18.9 18.1–19.7
CI, confidence interval
BMC Public Health 2009, 9:44 http://www.biomedcentral.com/1471-2458/9/44
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and BMI ≥ 30 OR 1.6, 95% CI 1.3, 2.0), abnormal waist
circumference (OR 1.2, 95% CI 1.1, 1.4), hypertension
(OR 1.2, 95% CI 1.1, 1.4), and dyslipidemia (OR 1.3,
95% CI 1.1, 1.5 (Table 4).
Discussion
This study shows a remarkably high prevalence of
chronic kidney disease (CKD) among individuals, aged
20 years and above, in an urban population in Iran. The
age adjusted prevalence of CKD, stages 3 to 5, in this
population based study in Iran is 14.9% (95% CI
14.2,15.5), and associated factors of CKD include older
age, female gender, increased BMI and abnormal waist
circumference, hypertension, and dyslipidemia.
The prevalence of CKD stages 3 to 5, as addressed in
several studies, differs in different countries and ethnic
groups worldwide. The prevalence of overall CKD in the
adult US population according to the third national
health and nutrition examination survey (NHANESIII)
was 11%, but the prevalence of CKD stages 3 to 5 was
4.7% [32]. The prevalence of CKD stages 1 to 4 in
Norway, estimated by MDRD study equation was 11.2%,
but the prevalence of CKD stages 3 and 4 was 4.6% [33].
In the Chinese general population aged 35 to 74 years,
the prevalences of CKD stage 3 and stage 4, estimated by
the MDRD study equation, were 2.4% and 0.14%,
respectively which are far lower than those of our results
[34]. Not too many studies have reported results similar
to ours. The prevalence of CKD stages 3 to 5 in the
Japanese general population predicted by the MDRD
equation modified by a Japanese coefficient was about
20% [13]. The prevalence of CKD stages 3 and 4 in
Thailand estimated recently using the simplified MDRD
equation was 13.8%, and the overall prevalence of CKD
in a study in Pakistan with a small sample size was
29.9% [35, 36].
T h ep r e v a l e n c eo fC K Ds t a g e s3t o5i no u rs t u d yi s
noticeably more than that reported from developed
countries. There might be some probable reasons for this
discrepancy. First, the risk factors of CKD including
diabetes and dyslipidemia in our population were more
than in other countries, although the prevalence of
hypertension and abnormal BMI were comparable to
other studies [2, 13, 37]. Second, the MDRD study
formula was developed based on 1628 participants in
whom GFR was measured with a reference method,
whereas these patients had CKD (mean GFR of 39.8 mL/
min/1.73 m
2). This is important because the relationship
between serum creatinine and GFR differs in healthy and
CKD populations and the MDRD formula is most
0
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Figure 2
Age-specific prevalence of CKD. Prevalence of CKD for
each age group by gender in 10,063 participants of the
Tehran Lipid and Glucose Study (TLGS) aged 20 years and
over is shown. Error bars represent standard error with 95%
confidence interval.
Table 3: CKD associated factors in individuals with and without CKD in 10 063 participants of the Tehran Lipid and Glucose Study
(TLGS) aged 20 years and over.
variable CKDn = 1897 Without CKDn = 8166 P value
Sex male 553(29.2) 3670(44.9) < 0.001
female 1344(70.8) 4496(55.1)
BMI(kg/m
2) ≤ 25 392(21.0) 3222(40.4)
25 to 30 852(45.6) 3099(38.8)
≥ 30 625(33.4) 1656(20.8) <0.001
Waist circumference abnormal 1049(55.3) 2300(28.2) <0.001
Diabetes diabetic 494(26.0) 887(10.9) <0.001
Hypertension hypertensive 982(51.8) 1611(19.7) < 0.001
Dyslipidemia dyslipidemic 1244(65.6) 3218(39.4) < 0.001
Smoking smoker 140(7.4) 1160(14.4) <0.001
Values are numbers (percentages); BMI, body mass index
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2, therefore the
MDRD study formula systematically underestimates GFR
in healthy populations [38]. Furthermore it is possible
that definition of CKD based on calculation using
MDRD formula is not reliable in Asian an Iranian
populations because this formula has not been validated
in these populations. This may lead to the prevalence of
CKD being overestimated in our study.
Many studies have evaluated various associated factors of
CKD, and in the present study there is a significant
association between each of the factors; age, female
gender, BMI, hypertension and CKD similar to the
previous studies [19, 39, 40]. Although age and gender
were included in the MDRD equation, they were
significant as independent associated risk factors for
CKD in our analysis. The higher prevalence of CKD in
female gender might be caused by lower physical
activity, and higher prevalence of cardio metabolic risk
factors in Iranian females. And the increasing prevalence
of decreased kidney function in older individuals might
result from an increase in age-related risk factors for the
development of CKD. While diabetes in most studies is
mentioned as an independent predictor for CKD, in our
study despite a high prevalence of diabetes in our
population, in the multivariate regression model it was
not significantly associated with CKD. A probable
explanation for this might be the recent development
of diabetes in our population, i.e. over than 70% of cases
were newly diagnosed. Another unexpected finding in
our study was that, in contrast to other studies,
n o n s m o k i n gw a sa s s o c i a t e dw i t hC K D ,a l t h o u g hi nt h e
multivariate analysis it did not remain in the model. This
can be explained by our low prevalence of smoking in
comparison to the other studies and also our inability to
take into account dose response relationship between
smoking and CKD. In addition, over two thirds of CKD
cases were females (70.8%), among whom there was no
significant difference between smoker and nonsmoker
percentages(3% versus 3.6%, P value = 0.32); whereas
most of smokers were males, they comprised less than
one third of CKD cases(29.2%). In the present study,
income and educational levels were the most important
determinants of socio-economic status of participants;
however because of the homogeneity of the geographical
location of participants' residential area, which is a
reliable indicator of their equal economic level; we
considered their education as the socio-economic criter-
ion. From this aspect 64% of the participants had the
educational level of high school diploma and above and
the relationship between CKD and under diploma was
significant (data not shown).
Our survey has both strengths and limitations. We
surveyed a large number of subjects during a popula-
tion-based study; however the limitations of our analysis
definitely deserve comment. Data regarding urinary
albumin and protein excretion were not collected, and
Table 4: Multivariate logistic regression for factors related to CKD in 10 063 participants of the Tehran Lipid and Glucose Study (TLGS)
aged 20 years and over.
Variable CKD(n = 1897) Total(n = 10063) Adjusted odds ratio 95%CI P
Age(years) 1.1 1.1–1.2 <0.001
Sex
male 553(29.2) 4223(42.0) 1.0 <0.001
female 1344(70.8) 5840(58.0) 3.1 2.6–3.7
BMI(kg/m
2)
<25 392(21.0) 3614(36.7) 1.0
25 to <30 852(45.6) 3951(40.1) 1.5 1.3–1.8 <0.001
≥ 30 625(33.4) 2281(23.2) 1.6 1.3–2.0 <0.001
Waist circumference
Normal 848(44.7) 6714(66.7) 1.0 0.002
Abnormal 1049(55.3) 3349(33.3) 1.2 1.1–1.4
Blood pressure
Normotensive 915(48.2) 7470(74.2) 1.0 0.004
Hypertensive 982(51.8) 2593(25.8) 1.2 1.1–1.4
Dyslipidemia
Normolipidemic 653(34.4) 5601(55.7) 1.0 <0.001
Dyslipidemic 1244(65.6) 4462(44.3) 1.3 1.1–1.5
Diabetes
Nondiabetic 1403(74.0) 8682(86.3) 1.0 0.6
Diabetic 494(26.0) 1381(13.7) 0.9 0.8–1.1
Smoking
Nonsmoker 1741(92.6) 8609(86.9) 1.0 0.778
Smoker 140(7.4) 1300(13.1) 1.1 0.9–1.3
BMI, body mass index; CI, confidence interval
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estimated in this population. Another limitation is that
we accepted participants to have CKD just with a single
creatinine measurement but we can not ensure that all
identified subjects with CKD had persistently impaired
renal function for at least 3 months. Although single
creatinine measurement is considered appropriate for
epidemiologic studies, by conducting only a one time
screening, we may have overestimated the CKD pre-
valence in Iran. Furthermore, we did not calibrate our
serum creatinine measurements to the Cleveland Clinic,
where the Modification of Diet in Renal Disease
(MDRD) eGFR equation was derived; nor did we
validate the MDRD eGFR equation in a local population,
and this could also cause an overestimation in the
prevalence of CKD. Finally, the cross-sectional design of
the present study makes it impossible to infer a causal
relationship between CKD and associated factors.
Conclusion
In summary, this high prevalence of chronic kidney
disease (CKD) in Iran has obvious implications for the
health of its citizens and for the appropriate allocation of
health-care resources. CKD has become an important
health problem associated with an alarming increase in
morbidity and mortality and with decreased quality of
life, although it can be prevented or its progression be
delayed; hence identifying the patients with CKD and
providing appropriate management is vital.
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